Global crises can accelerate technology. Disrupting traditional responses with innovation can result in untapped opportunities that become crucial tools for humanity.
This year, the Coronavirus pandemic could accelerate the evolution of drug and vaccine testing, as researchers are harnessing new technology to facilitate safety testing in people soon after preclinical work is completed on more than 60 emerging vaccine candidates. In the meantime, a bioengineering startup from South Korea could change the framework behind vaccine testing as we know it. Founded in 2017, CLECELL has focused on the research and development of artificial tissue and has gone on to create a respiratory epithelium model earlier this year using its proprietary 3D bioprinter, the U-FAB, as well as other bioprinting technology . What is so interesting about this model is that it is expected to become a testbed for the severe acute respiratory syndrome coronavirus (SARS-Cov-2), as well as […]
The digital revolution has changed how products are designed. Today digital data from a 3D model, produced...